Prevalence of H63D, S65C and C282Y hereditary hemochromatosis gene mutations in Slovenian population by an improved high-throughput genotyping assay by Cukjati, Marko et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
Prevalence of H63D, S65C and C282Y hereditary hemochromatosis 
gene mutations in Slovenian population by an improved 
high-throughput genotyping assay
Marko Cukjati*†1, Tomaž Vaupotič†1,2, Ruth Rupreht1 and Vladka Жurin-
Šerbec1
Address: 1Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000 Ljubljana, Slovenia and 2Institute of Biochemistry, University of Ljubljana, 
Medical Faculty, Vrazov trg 2, 1000 Ljubljana, Slovenia
Email: Marko Cukjati* - marko.cukjati@ztm.si; Tomaž Vaupotič - tomaz.vaupotic@mf.uni-lj.si; Ruth Rupreht - ruth.rupreht@gov.si; 
Vladka Жurin-Šerbec - vladka.curin@ztm.si
* Corresponding author    †Equal contributors
Abstract
Background:  Hereditary hemochromatosis (HH) is a common genetic disease characterized by
excessive iron overload that leads to multi-organ failure. Although the most prevalent genotype in HH is
homozygosity for C282Y mutation of the HFE gene, two additional mutations, H63D and S65C, appear to
be associated with a milder form of HH. The aim of this study was to develop a high-throughput assay for
HFE mutations screening based on TaqMan technology and to determine the frequencies of HFE mutations
in the Slovenian population.
Methods: Altogether, 1282 randomly selected blood donors from different Slovenian regions and 21 HH
patients were analyzed for the presence of HFE mutations by an in-house developed real-time PCR assay
based on TaqMan technology using shorter non-interfering fluorescent single nucleotide polymorphism
(SNP)-specific MGB probes. The assay was validated by RFLP analysis and DNA sequencing.
Results: The genotyping assay of the H63D, S65C and C282Y mutations in the HFE gene, based on
TaqMan technology proved to be fast, reliable, with a high-throughput capability and 100% concordant
with genotypes obtained by RFLP and DNA sequencing. The observed frequency of C282Y homozygotes
in the group of HH patients was only 48%, others were of the heterogeneous HFE genotype. Among 1282
blood donors tested, the observed H63D, S65C and C282Y allele frequency were 12.8% (95% confidence
interval (CI) 11.5 – 14.2%), 1.8% (95% CI 1.4 – 2.5%) and 3.6% (95% CI 3.0 – 4.5%), respectively.
Approximately 33% of the tested subjects had at least one of the three HH mutations, and 1% of them
were C282Y homozygotes or compound heterozygotes C282Y/H63D or C282Y/S65C, presenting an
increased risk for iron overload disease. A significant variation in H63D allele frequency was observed for
one of the Slovenian regions.
Conclusion: The improved real-time PCR assay for H63D, S65C and C282Y mutations detection is
accurate, fast, cost-efficient and ready for routine screening and diagnostic procedures. The genotype
frequencies in the Slovenian population agree with those reported for the Central European populations
although some deviations where observed in comparison with other populations of Slavic origin. Regional
distribution of the mutations should be considered when planning population screening.
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Background
Hereditary hemochromatosis (HH) is an inherited auto-
somal recessive disorder of iron metabolism. Due to
excessive intestinal absorption, iron accumulates in
parenchymal cells of the liver, pancreas, heart and other
organs with resultant damage to their structure and
impairment of their function. It is one of the most com-
mon genetic diseases in Caucasians with a prevalence of
nearly 1 in 300 [1]. Although the symptoms of the disease
are often nonspecific, much of the organ damage is irre-
versible once it has occurred. Early detection and therapy
is therefore very important as a part of preventive medi-
cine. The discovery of the responsible gene HFE in 1996
enabled molecular analysis to be included in the diagnos-
tic strategy for HH [2]. A number of different HFE muta-
tions have been reported so far. The majority of HH cases
(52–96%) in European regions are associated with a
homozygous 845G→A mutation within exon 4 of the
HFE gene, which results in amino acid change at position
282 from cysteine to tyrosine (C282Y) [1,2]. A second
mutant allele 187C→G detected with relatively high fre-
quency occurs within the exon 2 of the HFE gene where
aspartate replaces histidine at amino acid position 63
(H63D) [2]. The contribution of this allele to iron over-
load is most relevant in the case of combined heterozygos-
ity with C282Y allele (C282Y/H63D) [3,4]. The third
common mutation of HFE  is 193A→T substitution in
exon 2 (S65C) and was shown to be generally benign,
although a C282Y/S65C genotype may confer a slight
increase in disease risk, contributing to a mild disease
phenotype [4-6]. Many of the other HFE  mutations
described are private and rare, or they were found to be
significantly enriched only in certain regions [7]. There-
fore the frequencies of the HFE mutations in the general
population and in patients with clinically expressed dis-
ease have to be established in order to implement appro-
priate genetic tests in diagnostic and screening procedures
for HH. There are very few studies providing information
about the frequency of any of these three major HH muta-
tions in populations of Slavic origin [8-12]. Only one
study, based on RFLP method, is reported for the Slove-
nian population and is based on a limited number of sub-
jects [11]. However, we have no data yet about the
frequency of the HFE mutations in the Slovenian healthy
population and in patients with clinically expressed dis-
ease nor do we have data about distribution of HH geno-
types in different Slovenian regions.
Since HH is a genetic disorder that fulfils most of the
WHO criteria for large-scale population screening pro-
gram [13], the availability of a cost-effective method is an
important issue. Although genetic testing for HH is gener-
ally not recommended as the first step in a wide popula-
tion screening program because of uncertainty about the
natural history of the disease, age-related penetrance and
the psychosocial impact of genetic testing, its major role
in confirmation of the diagnosis cannot be overlooked.
Furthermore, family genetic testing performed among the
relatives of a newly diagnosed patient also enables detec-
tion of subjects in the pre-symptomatic phase [14,15].
Many PCR-based methods were reported for HH muta-
tion detection, however, real-time PCR-based assays with
TaqMan technology seems to be one of the most promi-
nent among them. The fluorescent TaqMan probes with
minor groove binder (MGB) are shorter and thus signifi-
cantly more specific for single nucleotide polymorphisms
(SNP) detection than standard DNA probes or allele spe-
cific PCR derivatives. The technology itself is completely
flexible and suitable for the extremely high-throughout
screening procedures since it combines the PCR amplifica-
tion and detection into a single step therefore also mini-
mizing the possibility of contamination [16]. An
objection of so far reported TaqMan-based assays for the
H63D and C282Y mutation detection was mainly the
improper design of the probes for HFE codon 63 screen-
ing, which are too long and overlap the polymorphic posi-
tion of the HFE codon 65 [16-18]. This could lead to the
misinterpretation of results obtained by those probes and
therefore more optimized probes are critical for a reliable
genotyping assay. It is worth to stress that the TaqMan
probes for the detection of the S65C polymorphism have
not been reported to date.
The aim of our work was (i) to develop an accurate, rapid
and cost-effective diagnostic assay based on the TaqMan
technology for the high-throughput detection of
187C→G, 193A→T and 845G→A mutations in the HFE
gene with validation on a small group of HH patients and
(ii) to determine the frequencies of HFE mutations in the
healthy population in Slovenia and to compare them with
some other European populations, especially those of
Slavic origin. The method described in this paper is now
available for routine diagnostic and screening procedures
for HH, opening new possibilities in preventive medicine
and possibly in screening for potential new blood donors.
Methods
Patients and control subjects
Voluntary, unpaid, unrelated whole blood donors who
attended blood donor sessions in 11 geographic regions
of the Republic of Slovenia from May 2002 to January
2003 were randomly selected for the population study.
Blood samples were obtained from 1282 blood donors,
934 male and 348 female, aged between 18 and 64 years
(40.4 ± 10.0 years for male and 39.7 ± 9.6 years for
female). In addition, 21 patients, 20 men and 1 woman,
with clinical and biochemical characteristics of HH who
underwent therapeutic phlebotomy were included in the
study. The mean age was 53 years for male patients (25 toBMC Medical Genetics 2007, 8:69 http://www.biomedcentral.com/1471-2350/8/69
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73 years) and 36 for female patient. In all patients the
diagnosis of HH was confirmed by quantitative phlebot-
omy with removal of more than 4 grams of iron. The study
was approved by the National medical ethics committee
number 66/05/2002 and informed consent was obtained
from all volunteers.
Genomic DNA isolation
Genomic DNA was isolated from 300 μL of buffy coat
using QIAamp Blood kit (Qiagen) according to the man-
ufacturer's instructions (Qiagen).
Real-time PCR
Primers and TaqMan® MGB probes were designed using
Primer Express v2.0 software (Applied Biosystem) based
on the published sequence of the HFE gene (GeneBank ID
NM000410). We carefully designed the probes for codons
H63D and S65C (SNPs being only six nucleotides apart)
so that they do not overlap. PCRs for each SNP were per-
formed in a single reaction tube for wild type and mutant
allele simultaneously on thermostable 96-well plate in
ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems). A 20 μL reaction consisted of TaqMan Uni-
versal PCR Master Mix with the passive reference ROX
(Perkin Elmer), 50 ng of genomic DNA, 300 nM of each
primers 5'-TTGGGCTACGTGGATGACC-3' and 5'-TCT-
GGCTTGAAATTCTACTGGAAA-3' for mutation H63D
and S65C or 5'-GAACCTAAAGACGTATTGCCAA-3' and
5'-AGATCACAATGAGGGGCTGATC-3' for mutation
C282Y and a corresponding pair of TaqMan MGB probes:
75 nM of each 5'-FAM-CTCATCATCATAGAACAC-NFQ-3'
(mutated) and 5'-VIC-CTCATGATCATAGAACAC-NFQ-3'
(wild-type) for H63D, 70 nM 5'-VIC-ACGGCGACACTCA-
NFQ-3' (mutated) and 90 nM 5'-FAM-CGGCGACTCTCA-
NFQ-3' (wild-type) for S65C or 45 nM 5'-VIC-CCTGG-
TACGTATATCT-NFQ-3' (mutated) and 55 nM 5'-FAM-
CTGGCACGTATATCT-NFQ-3' (wild-type) for C282Y
allele detection. PCR conditions were 2 min at 50°C, 10
min at 95°C, followed by 40 cycles of 15 sec at 95°C and
1 min at 60°C carried out by the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystem). Allele
discrimination was accomplished by running end point
detection using ABI PRISM 7900HT and SDS 2.0 software.
In addition, all results were confirmed by visual inspec-
tion of the real-time PCR multicomponent analysis plots.
RFLP analysis
Exons 2 and 4 of HFE gene were separately amplified by
PCR prior to the restriction analysis and sequencing in a
50 μL reactions consisted of 200 nM of each primer 5'-
TGTGGAGCCTCAACATCCT-3 and 5'-TGAAAAGCTCT-
GACAACCTCA-3' for exon 2 or 5'-TCCAGTCTTCCT-
GGCAA-3' and 5'-TTCTAGCTCCTGGCTCTCA-3' for exon
4, 10× PCR buffer (Perkin Elmer), 200 μM each dNTP
(Perkin Elmer), 1.25 mM MgCl2 (Perkin Elmer), 3 U Taq
DNA polymerase (Perkin Elmer) and 200 ng genomic
DNA. The thermal program consisted of 30 cycles with 20
sec at 94°C, 30 sec at 56°C and 1 min at 72°C. After PCR
amplification, restriction digests were performed directly
with the 25 μL of PCR mixtures by the addition of 5U BclI
(codon 63), HinfI (codon 65) or SnaBI (codon 282) and
corresponding buffers and incubated for 2 h at 50° for
BclI restriction or at 37°C for HinfI and SnaBI restriction.
The products were resolved on a 3% agarose gel. Geno-
types of HH patients were also confirmed by DNA
sequencing (Macrogen Inc., Seoul, Korea).
Statistical analysis
The results are expressed as means ± SD. Allele frequencies
are presented as % with 95% confidence interval (95%
CI) calculated by the Wilson procedure with a correction
for continuity. Fisher's exact test or χ2 test with Yates cor-
rection was used to compare the prevalence of HFE geno-
types among different groups by age and gender and to
compare allelic frequencies among different European
populations. The fit to the Hardy-Weinberg (H-W) equlib-
rium was tested by means of the χ2 test. Data analysis was
carried out using the statistical package SigmaStat 3.1
(Systat software Inc., San Jose, CA).
Results
The improved TaqMan MGB probes simultaneously and 
accurately discriminate 187C/G, 193A/T and 845G/A 
positions in the HFE gene
The universal cycling program of the real-time PCR was
performed at the same temperature conditions for all
probes designed in the study. The genotyping results
obtained by the real-time PCR analysis using the TaqMan
MGB probes are graphically presented for the case of S65C
mutation detection in Figure 1. The fluorescence of only
one of the two probes in the reaction mixture increased
exponentially in the case of the homozygous genotype,
either wild-type or mutant (Fig. 1A, upper panel repre-
sents 193A homozygous genotype), whereas a compara-
ble and simultaneous increase in fluorescence of both
probes at similar CT values was observed in the case of the
heterozygous genotype (Fig. 1A, second panel represents
193A/T heterozygous genotype). The reliability of the
codon 65 genotyping using HFE193A and HFE193T
probes in the presence of the polymorphisms at both
positions, 187 and 193, is shown in the case of the H63D/
S65C combined heterozygote. As shown in Fig. 1A, third
panel, the SNP at position 193 was successfully and accu-
rately identified without any interfering effects from the
SNP at position 187, which was not true for the probe that
covers both polymorphic positions at the same time (data
not shown). The scattered diagram showing only relative
end-point fluorescence intensities of both TaqMan MGB
probes for allelic discrimination of the HFE codon 65, is
shown in Figure 1B. Clustering of wild type homozygousBMC Medical Genetics 2007, 8:69 http://www.biomedcentral.com/1471-2350/8/69
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Validation of the real-time PCR assay for the 193A→T (S65C) mutation detection Figure 1
Validation of the real-time PCR assay for the 193A→T (S65C) mutation detection. (A) A multicomponent real-
time amplification plots created by the SDS software. The genotypes are indicated with bold. The CT values of individual probes 
for all genotypes are presented. Curves in the plots correspond to the indicated fluorophores or water (see the legend); ROX, 
internal reference dye; mse, mean squared error; NTC, no-template control. (B) End-point fluorescence detection is shown by 
the scattered diagram. Clustering of genotypes is based on the relative fluorescence from each well on 96-well plate. The 
expected area for 193 mutant homozygote samples clustering is indicated by red circle.BMC Medical Genetics 2007, 8:69 http://www.biomedcentral.com/1471-2350/8/69
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and heterozygous samples within the 96-well plate was
unambiguously evident from the end-point fluorescence
measurements, which makes allelic discrimination even
more routine and faster.
Validation of the real-time PCR assay by the RFLP analysis 
and DNA sequencing
Altogether, 21 HH patients were included for validation
of the real-time PCR. Only 10 of them (48%) were found
to be homozygous for C282Y mutation. Two patients
were homozygotes for H63D mutation. All the others
were of the heterogeneous genotypes: one patient was
C282Y heterozygote and two were H63D heterozygotes.
Among combined heterozygotes, two were H63D/C282Y
and two were H63D/S65C. Two HH patients (10%)
lacked any of the three mutations studied here. Positive
results were further confirmed by the RFLP analysis and
DNA sequencing. No discrepancies were observed
between the genotypes obtained by any of three methods.
Besides the confirmation of the three mutations in sam-
ples by two independent methods, we have gained stand-
ards for future testing.
Frequencies of the HFE gene mutation – H63D, S65C and 
C282Y – in Slovenian blood donors
Genotype frequencies were analyzed in the population of
Slovenian blood donors (Table 1). Among 1282 blood
donors tested, 30 (2.3%) were H63D homozygotes and
268 (20.9%) were H63D heterozygotes. Two (0.16%)
homozygotes and 89 (6.9%) heterozygotes for C282Y
mutation were found (Table 1). 47 samples (3.7%) were
S65C heterozygotes and no sample was identified as S65C
homozygote. Two, six and three samples were H63D/
S65C, H63D/C282Y and S65C/C282Y compound hetero-
zygotes, respectively. The calculated H63D, S65C and
C282Y allele frequencies were 12.8% (95% confidence
interval (CI) 11.5 – 14.2%), 1.8% (95% CI 1.4 – 2.5%)
and 3.6% (95% CI 3.0 – 4.5%), respectively (Table 2).
There were no significant deviations from the H-W equi-
librium in the blood donor population sample and no
difference in genotype frequency among blood donor
groups differing in gender or age.
Comparison of allele frequencies between different Slove-
nian regions revealed a significantly higher value for
H63D allele in Koroška (region 9) in the northeastern part
of Slovenia (21.3 % vs average 12.8 %; p = 0.005). Other
two alleles were more evenly distributed throughout Slov-
enia (Figure 2).
Discussion
The improved TaqMan MGB probes were optimized for 
high-throughput genotyping capability
We have optimized an accurate, rapid and high-through-
put method for HH mutation detection based on TaqMan
technology. Our contribution to the existing TaqMan-
based fluorescent probes for HFE mutations detection was
especially the construction of short specific MGB probes
for SNP detection at positions 187 and 193. Using the ABI
PRISM 7900HT Sequence Detection System and SDS soft-
ware, identification of samples with H63D, S65C and
C282Y mutations in the HFE gene was simple and highly
accurate. As shown in Figure 1, the real-time PCR results
were easy to interpret either from the multicomponent
amplification plot (Fig. 1A) or from the scattered diagram
of the end-point fluorescence measurements (Fig. 1B).
Genotype calls, as determined by real-time PCR analysis,
were 100% concordant with genotypes obtained by RFLP
and DNA sequencing.
We have also avoided the irregularity of many so far
reported probes for analysis of the HFE position 187 by
carefully designed short MGB probes for independent
determination of both 187 and 193 genotypes. Even
though the SNPs being only 6 nucleotydes apart the
probes do not overlap the positions 187 and 193 and
therefore do not interfere in the assay. Therefore, we have
improved accuracy of the H63D genotyping assay. To
date, our study is also the first time report of the popula-
tion based S65C polymorphism genotyping in the HFE
gene with the use of fluorescent TaqMan MGB probes
with a nonfluorescent quencher in a high-throughput
manner. Although we have improved real-time PCR assay
for H63D, S65C and C282Y mutations detection, much
larger surveys with HFE genotyping using several assay
systems should not be overlooked [19-21].
HFE polymorphism for C282Y was underrepresented in 
the group of Slovenian HH patients
A small group of Slovenian patients with a clinically
expressed disease who underwent therapeutic phlebot-
omy was included into our study to get positive controls
for the test validation as well as for later standard prepara-
tion. Although the number of subjects is too small to
make any serious conclusion it is evident from our results
that the frequency of C282Y homozygotes in the group of
HH patients is low (only 48%) when compared with
other European populations (52–96%) [1]. In 10% of HH
patients none of the three major mutations were found.
After further studies, including DNA sequencing, other
mutations elsewhere in the HFE gene, such as frame-shift
deletion c.471del in exon 3 resulting in a premature ter-
mination of a nonsense HFE protein, were recently found
in one of our HH patients [22]. Mutations in ferroportin1
or TFR2 genes might also be involved with the phenotypic
expression of HH symptoms in these patients and addi-
tional studies are on the way.BMC Medical Genetics 2007, 8:69 http://www.biomedcentral.com/1471-2350/8/69
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H63D allele frequencies differ among different Slovenian 
regions
To demonstrate the high-throughput capability of the
assay, we have performed an investigation on 1282 blood
donors from the Slovenian population as healthy repre-
sentatives by analyzing the occurrence of H63D, S65C
and C282Y single nucleotide polymorphisms within the
coding region of the HFE gene. Since Slovenia has only 2
million residents, the regionally representative group of
blood donors presents a very large sample. Allele frequen-
cies of H63D, S65C and C282Y mutations were 12.8%,
1.8% and 3.6%, respectively (Table 2). Based on our
results, homozygosity for the C282Y mutation was esti-
mated to occur in 0.16% of the selected population which
corresponds to 1 in 641 individuals. Compound hetero-
zygosity for C282Y/H63D occurred in approximately
0.5% of probands. Taken together, approximately 1% of
the Slovenian population are C282Y homozygotes or
compound heterozygotes C282Y/H63D or C282Y/S65C,
which all represent an increased risk for iron overload.
More than 33% of tested subjects had at least one of the
three mutations, linked to HH.
Comparing allele frequencies among different Slovenian
regions revealed significantly higher frequency of H63D
allele in one of northeastern regions (Fig. 2). The differ-
ence could be explained by the fact that the observed
region is surrounded by mountains, characterized by rela-
tively low migratory fluxes, and therefore a relatively iso-
lated geographic area. Although the sample size for this
region is too small to check for H-W equilibrium, the fre-
quencies of H63D genotypes are within expected values.
Regional distribution of H63D allele should be taken into
account when planning wide population screening.
HFE polymorphism prevalence in Slovenian population 
differs from those of other Slavic populations
In Europe, the population movements have contributed
to the ethnic groups, cultures, and consequently, inherit-
ance mixing. HH is one of the genetic diseases whose dis-
tribution is directly related to the population movements.
The C282Y allele frequencies in the general population
are distributed among a decreasing cline from northwest
to southeast Europe with a higher prevalence in the pop-
ulations having a heavier Celtic or Viking component [23-
25]. In Table 3, the frequency of the H63D, S65C and
C282Y mutations observed in the Slovenian population
were compared with the frequencies observed in some
other European populations. The prevalence of C282Y
mutation in the Republic of Slovenia (3.6%) correlates
with the reported northwest to southeast gradient [1] and
geographic position of Slovenia. Compared to other
nations of Slavic origin the frequency of the C282Y muta-
tion is higher, but not significantly, comparing to Poland
(3.1%) [10], the Czech Republic (3.4%) [8] and Croatia
(3.3%) [11], and lower than in Bosnia and Herzegovina
(4.0%) [12].
Interestengly, the C282Y frequency significantly differs
from the population of Serbia and Montenegro (1.6%)
[26], also Slavic in origin. Obviously, there is a considera-
bly high difference in C282Y allele frequencies among
nations of Slavic origin, which could support a late intro-
duction of the mutation in Slavic nations or, alternatively,
that more time passed, than generally believed, from the
close connections among Slavic nations. In contrast, the
Table 2: Allele frequencies of H63D, S65C and C282Y mutation 
in the HFE gene in Slovenian blood donors.
HFE alleles Allele frequency % (95% CI)
H63D 12.8 (11.5 – 14.2)
S65C 1.8 (1.4 – 2.5)
C282Y 3.6 (3.0 – 4.5)
Table 1: Genotype frequencies of H63D, S65C and C282Y mutations in HFE gene in Slovenian blood donors.
Genotype Frequency
H63D S65C C282Y n % (95% CI)
-/- -/- -/- 857 66.8 (64.2–69.4)
+/- -/- -/- 260 20.3 (18.1–22.6)
-/- -/- +/- 80 6.2 (5.0–7.7)
-/- -/+ -/- 42 3.3 (2.4–4.5)
+/+ -/- -/- 30 2.3 (1.6–3.4)
-/- -/- +/+ 2 0.16 (0.03–0.63)
-/- +/+ -/- 0 -
+/- -/- +/- 6 0.47 (0.19–1.07)
+/- +/- -/- 2 0.16 (0.03–0.63)
-/- +/- +/- 3 0.23 (0.06–0.74)
Total 1282
The presence or absence of the indicated mutation is shown by + or -, respectively.BMC Medical Genetics 2007, 8:69 http://www.biomedcentral.com/1471-2350/8/69
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H63D, S65C and C282Y allele frequency distribution in 1282 blood donors among different Slovenian regions Figure 2
H63D, S65C and C282Y allele frequency distribution in 1282 blood donors among different Slovenian regions. 
A) Regional distribution of HFE polymorphisms. The regions, numbered from 1 to 11, are arranged from west to east, and 
marked on the map below. Average frequency for Slovenia is presented in the last column (total). In the region 9 H63D allele 
frequency is significant higher comparing to other regions (p = 0.005). (B) Geographic regions of Slovenia.
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frequency of C282Y mutation in Slovenia is considerably
higher than in the Modena region of Italy [27].
H63D mutation is more frequent and more uniformly
distributed among European nations [1]. The highest fre-
quencies of the H63D mutation among Basques and Cat-
alans in Spain suggest that this mutation may have its
origin in the early West European populations before the
Indo-European expansion [28]. Considering the allele fre-
quency of H63D mutation (12.8%), Slovenia has lower
frequency when compared with Poland (16.2%), the
Czech Republic (15.0%), Croatia (14.5%) and Serbia and
Montenegro (15.7%). Among nations of Slavic origin
only Bosnia and Herzegovina was reported to have lower
H63D frequency (11.3 %) although the difference is not
significant.
The allele frequency of S65C mutation in the Slovenian
population was estimated to be 1.8%, which is very close
to Croatia (1.8%) and Serbia and Montenegro (1.6%).
Interestingly, the S65C allele frequency is also close to the
French population in Brittany (1.95%) [4] and higher if
compared with the Ossola region in Northern Italy
(0.7%) [29]. For the S65C mutation, the population data
are so far too scanty to allow for tracing its origin.
Conclusion
In conclusion, an improved TaqMan high-throughput val-
idated assay, described in this paper is ready for wider
screening application. The observed genotype frequency
for H63D, S65C and C282Y mutations in the Slovenian
population agrees with those reported for the Central
European populations, although some deviations were
observed in comparison with populations of Slavic origin.
A revision of restrictions by the national guidelines on
blood donation from otherwise healthy HH patients
should be done before the implementation of population
screening for HH in order to promote more blood donors
necessary to mantain adequate blood supply.
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